Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Effect of bempedoic acid on incretin axis and systemic and liver inflammation: a pilot, monocentric study

Title: Effect of bempedoic acid on incretin axis and systemic and liver inflammation: a pilot, monocentric study
Authors: Rovera C.; Del Zoppo A.; Petralli G.; Moriconi D.; Rossi C.; Distaso M.; Brunetto M. R.; Ferrannini E.; Raggi F.; Solini A.
Contributors: Rovera, C.; Del Zoppo, A.; Petralli, G.; Moriconi, D.; Rossi, C.; Distaso, M.; Brunetto, M. R.; Ferrannini, E.; Raggi, F.; Solini, A.
Publication Year: 2025
Collection: ARPI - Archivio della Ricerca dell'Università di Pisa
Subject Terms: Bempedoic acid; GLP-1; Inflammation; Liver steatosis
Description: Background and aims: Bempedoic Acid (Bemp-Ac) is able to reduce LDL cholesterol and cardiovascular events in hypercholesterolemic subjects with a wide risk profile, and is the recommended first line therapy when statins are not tolerated. We explored its efficacy, tolerability, metabolic, systemic and liver anti-inflammatory effects in non-diabetic individuals. Methods and results: Twenty-five statin-intolerant subjects were treated for three months with Bemp-Ac 180 mg/day. Metabolic profile, hormones regulating glucose metabolism and inflammatory markers were measured. Liver status was assessed through Fibroscan. Data were compared with those obtained in twelve subjects treated with Ezetimibe 10 mg/day, following the same protocol. Bemp-Ac reduced total cholesterol by about 25 %. Kidney function did not vary. The relevant anti-inflammatory effect of Bemp-Ac was confirmed by the significant improvement of liver condition (reduced CAP and LS, p = 0.042 and p = 0.008 respectively), persisting after adjustment for confounders; a reduction in white blood cells and cytokines levels was also observed. A detailed evaluation of glucose metabolism unveiled a significant reduction of GLP-1 and insulin, while glucagon and GIP were not influenced by the treatment with Bemp-Ac. Conclusion: Beside its hypolipidemic effects, Bemp-Ac reduces liver steatosis and inflammation and modulates glucoregulatory hormones in statin-intolerant, non-diabetic individuals.
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/41073213; journal:NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES; https://hdl.handle.net/11568/1339351
DOI: 10.1016/j.numecd.2025.104373
Availability: https://hdl.handle.net/11568/1339351; https://doi.org/10.1016/j.numecd.2025.104373
Accession Number: edsbas.8B5C0BF6
Database: BASE